Table 2.
Comparison of the initial characteristics (baseline) of the control group (n=45) and the intervention group (n=45)
| Characteristics | CG | IG | P-valuea |
|---|---|---|---|
| Age (average ± CI, years) | 41.5 (39.2–43.8) | 42.0 (39.1–44.9) | 0.778 |
| Men, % (n) | 55.5 (25) | 55.5 (25) | 1.000 |
| Ethnicity, % (n) | |||
| Caucasian | 64.4 (29) | 57.8 (26) | 0.522 |
| Biracial | 24.4 (11) | 28.9 (13) | 0.816 |
| Asian | 0.0 (0) | 2.2 (1) | 0.320 |
| Black | 11.1 (5) | 11.1 (5) | 1.000 |
| HIV diagnosis (average ± CI, years) | 8.3 (6.9–9.7) | 8.7 (6.2–11.2) | 0.758 |
| Treatment time (average ± CI, years) | 7.5 (6.3–8.7) | 6.7 (5.2–8.2) | 0.409 |
| Tablets per dayb (average ± CI, number) | 8.6 (7.1–10.1) | 8.6 (7.5–9.7) | 0.961 |
| CD4+ basal lymphocytes (average ± CI, cells/mm³) | 228.9 (164.4–293.5) | 260.7 (175.8–345.6) | 0.589 |
| Basal viral load <50 copies/mm³ (%) | 34.0 | 44.0 | 0.285 |
| Basal hemoglobin (average ± CI, g/dL) | 12.4 (11.6–13.2) | 12.7 (12.2–13.2) | 0.411 |
| Presented comorbidities, % (n) | 93.3 (42) | 88.8 (40) | 0.464 |
| Hepatitis C | 33.3 (15) | 13.3 (6) | 0.025 |
| Smoking | 28.8 (13) | 11.1 (5) | 0.035 |
| Neurotoxoplasmosis | 13.3 (6) | 15.5 (7) | 0.767 |
| Antiretroviral regimen, % | |||
| Zidovudine/lamivudine + efavirenz | 15.5 | 15.4 | 0.910 |
| Lamivudine + tenofovir + lopinavir/ritonavir | 22.2 | 7.7 | 0.212 |
| Zidovudine/lamivudine + tenofovir + lopinavir/ritonavir | 11.1 | 15.4 | 0.753 |
| Zidovudine/lamivudine + lopinavir/ritonavir | 11.1 | 0.0 | 0.198 |
| Lamivudine + tenofovir + efavirenz | 11.1 | 15.4 | 0.753 |
| Others | 28.9 | 46.1 | 0.150 |
Notes:
a
Student’s t-test considering two-tailed test
b
prescription medicines, not only antiretroviral agents.
Abbreviations: CG, control group: not assisted by the pharmacist; CI, confidence interval; HIV, human immunodeficiency virus; IG, intervention group: assisted by the pharmacist.